- Home
- AARD vs ACV Comparison
AARD vs ACV Comparison
Compare AARD & ACV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AARD
- ACV
- Stock Information
- Founded
- AARD 2017
- ACV 2015
- Country
- AARD United States
- ACV United States
- Employees
- AARD N/A
- ACV N/A
- Industry
- AARD Biotechnology: Pharmaceutical Preparations
- ACV Finance/Investors Services
- Sector
- AARD Health Care
- ACV Finance
- Exchange
- AARD Nasdaq
- ACV Nasdaq
- Market Cap
- AARD 277.9M
- ACV 253.6M
- IPO Year
- AARD 2025
- ACV N/A
- Fundamental
- Price
- AARD $11.22
- ACV $24.85
- Analyst Decision
- AARD Strong Buy
- ACV
- Analyst Count
- AARD 7
- ACV 0
- Target Price
- AARD $31.43
- ACV N/A
- AVG Volume (30 Days)
- AARD 151.9K
- ACV 38.8K
- Earning Date
- AARD 11-14-2025
- ACV 01-01-0001
- Dividend Yield
- AARD N/A
- ACV 9.20%
- EPS Growth
- AARD N/A
- ACV N/A
- EPS
- AARD N/A
- ACV N/A
- Revenue
- AARD N/A
- ACV N/A
- Revenue This Year
- AARD N/A
- ACV N/A
- Revenue Next Year
- AARD N/A
- ACV N/A
- P/E Ratio
- AARD N/A
- ACV N/A
- Revenue Growth
- AARD N/A
- ACV N/A
- 52 Week Low
- AARD $4.88
- ACV $16.82
- 52 Week High
- AARD $19.58
- ACV $23.74
- Technical
- Relative Strength Index (RSI)
- AARD 39.08
- ACV 60.95
- Support Level
- AARD $10.65
- ACV $24.22
- Resistance Level
- AARD $17.94
- ACV $25.20
- Average True Range (ATR)
- AARD 0.95
- ACV 0.48
- MACD
- AARD -0.64
- ACV -0.05
- Stochastic Oscillator
- AARD 7.82
- ACV 51.28
About AARD Aardvark Therapeutics Inc.
Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.
About ACV Virtus Diversified Income & Convertible Fund of Beneficial Interest
Virtus AllianzGI Diversified Income & Convertible Fund is a diversified, limited-term, closed-end management investment company. The fund's investment objective is to provide total return through a combination of current income and capital appreciation while seeking to provide downside protection against capital loss. It invests in a diversified portfolio of convertible securities, income-producing equity securities, and income-producing debt and other instruments of varying maturities, of which a majority of the managed assets are invested in convertibles.